Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A Novel Tetravalent Bispecific Immune Cell Engager Activates Natural Killer Cells to Kill Cancer Cells without Mediating Fratricide

Antibodies(2024)10.3390/antib13030075Source: DataRank Database

A Novel Tetravalent Bispecific Immune Cell Engager Activates Natural Killer Cells to Kill Cancer Cells without Mediating Fratricide is a research paper published in Antibodies (2024). On theSindex it has a DataRank of 0. It has been cited 2 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.31)OA: goldTopics (27)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Shahryar Khoshtinat Nikkhoi ORCID,Hajar Owji,Geng Li ORCID,Mohammad Massumi ORCID,Jessica A. Cervelli

Live enrichment

PubMed:39311380 PMC:PMC11417942 OpenAlex:https://openalex.org/W4402393397

NIH/NCI

Grant: R01CA251438

NIH/NCI

Grant: U01HL150852

NCI NIH HHS

Grant: P30 CA072720

National Institutes of Health

Grant: 5R01CA251438-04

Stem Cell-based Platform for Targeted Enzyme/Prodrug Therapy of Recurrent Ovarian Cancer

National Institutes of Health

Grant: 1U01HL150852-01

Rutgers Optimizes Innovation (ROI) Program

National Institutes of Health

Grant: 3P30CA072720-07S2

CANCER CENTER SUPPORT GRANT

FWCI

0.31

Citation Percentile

0.5%

Citation Trend

2025

goldLicense: cc-by

journalhttps://www.mdpi.com/2073-4468/13/3/75/pdf?version=1725964168

publisherhttps://www.mdpi.com/2073-4468/13/3/75/pdf?version=1725964168

publisherhttps://www.mdpi.com/2073-4468/13/3/75/pdf

journalhttps://doi.org/10.3390/antib13030075

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39311380

Fields of Study

Immune Cell Function and InteractionCAR-T cell therapy researchImmunotherapy and Immune Responses

Keywords

Immune systemCancer cellCancer researchCellChemistryCancerCell biologyBiologyMolecular biologyImmunologyBiochemistryGeneticsVhhCd16aFratricideDaratumumabBikeLank92Multi-paratope AntibodyImmune Cell EngagerTetravalent Bispecific AntibodyImmunologic diseases. AllergyRC581-607Article

Sustainable Development Goals

SDG 0: Good health and well-being